Floatz logo

Ozanimod

Multiple Sclerosis

The University of Texas at DallasSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB

View all 50 →

Same molecule, other indications

Ozanimod is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
digestive system disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →